MedPath

RYLAZE

RYLAZE

Approved
DIN Number

02530406

Drug Class

Human

Market Date

May 3, 2023

Company
HC

JAZZ PHARMACEUTICALS IRELAND LIMITED

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02530406
AIG Number0164041001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription ,  Schedule D
A
ATC Code
L01XX02 ASPARAGINASE
Product Specifications
Dosage FormSolution
Route of AdministrationIntramuscular
AHFS Classification44:00.00
Health Canada Classification

ACTIVE INGREDIENTS (1)

CRISANTASPASEActive
Strength: 10 MG / 0.5 ML
Monograph: CRISANTASPASE

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.